Algernon Appoints Novotech As CRO for Phase 2 Coronavirus Ifenprodil Trial
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it has chosen to appoint award winning Novotech as the contract research organization (CRO) for a planned physician initiated study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea. Novotech is an internationally recognized full service CRO known for its experience across […]
Algernon Announces Filing of U.S. FDA Pre-Ind Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA. This initiates formal communications with the U.S. FDA regarding the development of the company’s repurposed drug NP-120 (Ifenprodil) for the treatment and prevention of acute lung injury (ALI) and […]
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it is exploring the potential of using NP-120 (Ifenprodil) as a novel treatment for COVID-19, also known as the coronavirus. A recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with H5N1 infected […]
Algernon Signs Novotech Up for Midstage Respiratory Therapy Test
UF startup Algernon Pharmaceuticals has chosen contract research organization (CRO) Novotech to help run its phase 2 idiopathic pulmonary fibrosis and chronic cough trial for its experimental med NP-120 (Ifenprodil). The study is slated to start in the second quarter of 2020, and Algernon will tap Novotech’s experience across the Asia-Pacific region. Also, the CRO […]
Algernon Pharmaceuticals Finding New Uses for Safe, Older Drugs
Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, sat down with Proactive‘s Steve Darling at the 12th annual LD Micro Conference in Bel Air, California. The Vancouver, British Columbia-based company, is advancing its lead compounds for non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, […]
Algernon Pharmaceuticals Provides Update on Its Planned Phase II Clinical Trial
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, provided an update to the market on its planned phase II clinical trial and its additional plans for 2020. The company is focused on developing repurposed therapeutic drugs. Drug repurposing (also known as re-profiling, re-tasking or therapeutic switching) […]
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies
Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, is pleased to report that its lead drugs for non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) Bemethyl (NP-135) and Bromantane (NP-160), exhibited highly statistically significant anti-fibrotic activity and outperformed known anti-fibrotic agents Telmisartan and Cenicriviroc. “We are planning off-label phase II clinical trials for […]
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56 Percent
Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, announced that NP-120, its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), showed superiority in reducing fibrosis over two globally approved therapies for IPF, Pirfenidone and Nintedanib, in a well-established in vivo animal model study of IPF. Learn more about Algernon Pharmaceuticals’ […]
Breathtec Announces Name Change to Algernon Pharmaceuticals
UF startup Breathtec Biomedical Inc. is pleased to announce that as a result of the strength of the data from its Nash Pharmaceuticals pre-clinical research program, it will be changing its name to Algernon Pharmaceuticals Inc. The change will take place before the market opens on February 19, and the Company’s ticker symbol will change from […]